ArticleThe world journal of men's health2026
A Novel
Article in The world journal of men's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeIn traditional Chinese medicine, benign prostatic hyperplasia (BPH) is attributed to MATERIALS AND
methodsNetwork pharmacology was applied to identify potential molecular targets and pathways, and the predicted mechanisms were experimentally validated in BPH-1 cells and in rats with testosterone propionate (TP)-induced BPH.
resultsWG alleviated prostate enlargement in rats with TP-induced BPH. Network pharmacology predicted that WG could modulate key regulators of cell cycle progression and apoptosis. Consistently, WG suppressed androgen receptor (AR) signaling in both BPH-1 cells and rats with TP-induced BPH. WG also inhibited G1/S checkpoint regulators and induced apoptosis by reducing B-cell lymphoma (Bcl)-2 and Bcl-xL/Bcl-2 associated X protein ratios, leading to the activation of caspase-9 and -3. Through these actions, WG prevented the activation of the AR signaling pathway, promoted cell cycle arrest, and triggered apoptosis, thereby mitigating BPH progression.
conclusionsThese findings, supported by both network pharmacology predictions and experimental data, suggest that WG has promising therapeutic potential for the treatment of BPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.